Published July 1, 2019
| Version v1
Journal article
Open
Optimisation of RNP electroporation in SU DIPG IV patient derived DIPG cell line
- 1. Structural Genomics Consortium, University of Oxford
Description
A report describing the protocol used to optimise the electroporation of RNPs into the patient derived DIPG cell line (SU-DIPG-IV). Electroporation was performed with the Neon electroporation system. RNPs consisting of sgRNA and AlexaFluor488 anti-mouse antibodies as a proxy for the Cas9/sgRNA RNPs to be delivered for CRISPR/Cas9 mediated genome editing.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
2019 06 SU DIPG IV electroporation optimisation report.pdf
Files
(3.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:53b9e6259df943309f733686eb8309a9
|
2.6 MB | Preview Download |
|
md5:b675157564a6adbdf0d13d9a67a84166
|
667.5 kB | Preview Download |